EBMT Meeting | Conference

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

April 7th 2021

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Cilta-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

March 17th 2021

Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

March 17th 2021

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

March 17th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

March 16th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

March 16th 2021

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Liso-Cel Administration in Relapsed/Refractory LBCL Successful in Inpatient, Outpatient Settings at Nonuniversity Centers

March 16th 2021

Lisocabtagene ciloleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD

March 16th 2021

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

March 15th 2021

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.